<DOC>
	<DOCNO>NCT00427908</DOCNO>
	<brief_summary>This study 2 phase , vaccination phase long-term follow-up phase . In vaccination phase study , new meningococcal vaccine 134612 evaluate child use Mencevax™ ACWY ( child 2 year ) Meningitec™ ( child 2 year ) control . In long-term follow-up phase study , long-term protection offer vaccine assess 5 year vaccination . Subjects randomize primary vaccination phase study ; new subject enrol long-term follow-up phase study .</brief_summary>
	<brief_title>Study Children Evaluate Non-Inferiority Persistence 5 Years GSK Bio Meningococcal Vaccine 134612</brief_title>
	<detailed_description>Subjects enrol 3 age stratum . Subjects include two year age receive either GSK Biologicals meningococcal vaccine 134612 Mencevax™ ACWY , subject two year age receive either GSK Biologicals meningococcal vaccine 134612 Meningitec™ . All subject 7 blood sample take : prior one month vaccination one , two , three , four five year vaccination . The Protocol Posting update order comply FDA Amendment Act , September 2007 .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent guardian comply requirement protocol . A male female , include , 1 10 year age time vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Previously complete routine childhood vaccination best his/her parents/guardians ' knowledge . For primary phase : Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior vaccine dose . Planned administration/ administration vaccine foreseen study protocol within one month dose vaccine ( ) . Previous vaccination meningococcal polysaccharide vaccine serogroup A , C , W , and/or Y ( subject 6 year ) within last five previous year ( subject 6 year old ) . Previous vaccination meningococcal polysaccharide conjugate vaccine serogroup A , C , W , and/or Y . Previous vaccination tetanus toxoid contain vaccine within last 28 day . History meningococcal disease due serogroup A , C , W , Y . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . For long term persistence phase : History meningococcal serogroup A , C , W , and/or Y disease . Administration meningococcal polysaccharide meningococcal polysaccharide conjugate vaccine plan protocol .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Meningococcal serogroups A , C , W-135 and/or Y disease</keyword>
	<keyword>Conjugate vaccine</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Persistence</keyword>
	<keyword>Non-inferiority</keyword>
</DOC>